NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhibitors have been proposed as a...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Galvani, Elena, Sun, Jing, Leon, Leticia G., Sciarrillo, Rocco, Narayan, Ravi S., Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A.M., Alfieri, Roberta R., Heynen, Guus J., Bernards, René, Smit, Egbert F., Pao, William, Peters, Godefridus J., Giovannetti, Elisa
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2015
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4767465/
https://ncbi.nlm.nih.gov/pubmed/26015408
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍